Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as a sterile powder for intravenous use. It is employed in the treatment of metastatic colorectal cancer and as adjuvant therapy for colon cancer in adult patients, and is indicated for use under specialist oncology supervision.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution.

Irinotecan Accord is a chemotherapy agent used in colorectal cancer treatment pathways. - Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine therapy. - Adjuvant colon cancer: reduces risk of recurrence after surgical resection. - Advanced colorectal adenocarcinoma: employed as part of combination chemotherapy regimens.

Irinotecan Accord may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate nausea during or after infusion. - Diarrhea: often self‑limited but may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: generalized tiredness during treatment cycles.

Serious or Rare Side Effects: - Severe neutropenia or febrile neutropenia: requires immediate medical attention. - Severe diarrhea or colitis: can lead to dehydration and electrolyte imbalance. - Hepatic toxicity: elevated liver enzymes or bilirubin. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

Before initiating Irinotecan Accord, several safety measures should be observed. - Baseline assessment: obtain complete blood count and liver function tests prior to therapy. - Monitor hematology: perform regular CBCs to detect neutropenia early. - Assess gastrointestinal toxicity: watch for severe or persistent diarrhea. - Avoid concurrent strong CYP3A4 inhibitors: may increase drug exposure and toxicity. - Pregnancy and lactation: use only if potential benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan Accord can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). - UGT1A1 inhibitors (e.g., atazanavir, indinavir). - Concurrent myelosuppressive agents (e.g., other cytotoxics).

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine). - Anticoagulants (e.g., warfarin) – increased bleeding risk. - Nephrotoxic drugs – monitor renal function and dosage adjustments.